ConductScience.org, home

Comparison · NCT01857310-e8d438f4

Folic Acid and Zinc Supplementation vs Placebo: Structural Malformations

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Folic Acid and Zinc Supplementation vs Placebo: Structural Malformations. Trial comparisons, record NCT01857310-e8d438f4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01857310-e8d438f4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01270.007690.0208wilson
Risk in group 20.01180.007050.0197wilson
Risk difference, group 1 minus group 20.000844-0.008510.0103newcombe hybrid score
Risk ratio, group 1 over group 21.070.522.21log
Odds ratio, group 1 over group 21.070.5152.23log
Number needed to treat, for one more participant with the outcome on Folic Acid and Zinc Supplementation than on Placebo1,180from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Folic Acid and Zinc Supplementation5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.~5 mg folic acid and 30 mg elemental zinc151,185OG000
Group 2PlaceboMatching placebo, taken orally daily for 6 months.~Placebo Comparator: Placebo141,185OG001

Outcome

Type
SECONDARY
Title
Structural Malformations
Description
Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes
Time frame
Delivery
Population

Source ClinicalTrials.gov

Trial

Title
Folic Acid and Zinc Supplementation Trial (FAZST)
NCT number
NCT01857310
Phases
NA
Conditions
Pregnancy, Live Birth, Spontaneous Abortion
Interventions
5 mg folic acid and 30 mg elemental zinc, Placebo Comparator: Placebo
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Results first posted
2020-11-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01857310-e8d438f4